CompletedNot Applicable

Treatment Patterns and Key Healthcare Resource Use in Acute Myeloid Leukemia (AML) With or Without FMS-like Tyrosine Kinase-3 (FLT3) Mutation Study Based on Retrospective Chart Review

United States1,027 participantsStarted 2014-06-02

Plain-language summary

The purpose of this study is to retrospectively evaluate the treatment patterns and AML-related key healthcare resource use among AML patients, stratified by FLT3 mutation status, intensive chemotherapy (IC) eligibility, and relapsed or refractory (R/R) status.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Confirmed diagnosis of AML but NOT acute promyelocytic leukemia (APL) * Known FLT3 mutation status * Under the care of the participating physician during the past 3 years OR from the initial diagnosis of AML * The medical records related to AML for the patient are available to the physician and can be abstracted for this study * The medical records contains complete information on treatments and AML-related hospitalization, including admission date, length of stay, and reason of hospitalization * Initiation date of first treatment after AML diagnosis OR date of being classified as relapsed from or being refractory to initial treatment (R/R) is between January 1, 2013 and December 31, 2015 Exclusion Criteria: * Not applicable

What they're measuring

Treatment patterns assessed by drugs initiated

Timeframe: Up to 3 years

Treatment patterns assessed by dosage

Timeframe: Up to 3 years

Treatment patterns assessed by duration of treatment

Timeframe: Up to 3 years

Treatment patterns assessed by whether remission was achieved.

Timeframe: Up to 3 years

Treatment patterns assessed by an event

Timeframe: Up to 3 years

AML-related healthcare resource use assessed by number of hospitalizations and lengths of ICU hospital stay

Timeframe: Up to 3 years

AML-related healthcare resource use assessed by number of emergency department (ED) visits

Timeframe: Up to 3 years

AML-related healthcare resource use assessed by number of outpatient visits

Timeframe: Up to 3 years

Trial details

NCT IDNCT03047083

SponsorAstellas Pharma Global Development, Inc.

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2016-03-18

View on ClinicalTrials.gov More Acute Myeloid Leukemia (AML) trials

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Treatment patterns assessed by drugs initiated

Timeframe: Up to 3 years

Treatment patterns assessed by dosage

Timeframe: Up to 3 years

Treatment patterns assessed by duration of treatment

Timeframe: Up to 3 years

Treatment patterns assessed by whether remission was achieved.

Timeframe: Up to 3 years

Treatment patterns assessed by an event

Timeframe: Up to 3 years

AML-related healthcare resource use assessed by number of hospitalizations and lengths of ICU hospital stay

Timeframe: Up to 3 years

AML-related healthcare resource use assessed by number of emergency department (ED) visits

Timeframe: Up to 3 years

AML-related healthcare resource use assessed by number of outpatient visits

Timeframe: Up to 3 years